Open an account

PDS Biotechnology

PDSB · NASDAQ

$0.9605+$0.044 (+4.80%)TodayMarket closed ·
Prev close $0.9165

PDSB analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $4.25 (+342.5% upside)

Low
$3.03
Now
$0.9605
High
$5.25

Upgrades and downgrades

The latest rating actions, newest first

PDSB analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 8, 2026MaintainsBuy
HC Wainwright & Co.Aug 26, 2026MaintainsBuy
HC Wainwright & Co.Aug 13, 2026MaintainsBuy
HC Wainwright & Co.Apr 15, 2026MaintainsBuy
B. Riley SecuritiesNov 25, 2025MaintainsBuy
HC Wainwright & Co.Nov 13, 2025MaintainsBuy

The case for and against

Updated Oct 17, 2026

Bull case

PDS Biotechnology is attractive fundamentally because management has sharpened capital allocation around PDS0301 after encouraging mCRC response and survival signals, while preserving PDS0101 through partnering rather than draining resources into a capital-intensive registrational program in a crowded HNSCC market. The Nant-led PIPE, up to $22.55M with $5.6M cash at the end of 2Q26, materially reduces near-term funding risk and supports the focused strategy even after some dilution and debt repayment. Its appeal is further reinforced by PDS0301 data showing 7/9 responses at six months, 22-patient survival near 80% at 24 months, and a planned roughly 90-patient randomized Phase 2b study that could broaden commercial reach if benefit is confirmed.

Bear case

PDS Biotechnology is burdened by a fragile financing profile, having ended 2Q26 with just $5.6M in cash while management said about $15M is needed to fund the randomized mCRC study through interim analysis and another $15M to support operations over the same period. The company’s 36% workforce reduction and $842K 3Q26 restructuring charge may lower burn, but they also signal severe capital constraints and a narrowed strategic focus that reflects pressure rather than strength. With valuation still heavily dependent on PDS0301 and PDS0101, and with failed or inconclusive trials, partnership risk, and substantial dilution explicitly cited, the stock’s fundamentals remain highly vulnerable.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.